Trials / Unknown
UnknownNCT01089270
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Tel-Aviv Sourasky Medical Center · Other Government
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms. Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes. The examination results will be given to the participants by a doctor from the neurology department.
Conditions
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-03-01
- First posted
- 2010-03-18
- Last updated
- 2010-03-18
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01089270. Inclusion in this directory is not an endorsement.